Article
Impact of added fluvastatin to standard-of-care treatment on sustained virological response in naïve chronic hepatitis C Patients infected with genotypes 1 and 3.
Intervirology - 1 Jan 2014
Selic Kurincic Tanja, Lesnicar Gorazd, Poljak Mario, Meglic Volkar Jelka, Rajter Mojca, Prah Janja, Baklan Zvonko, Kotar Tadeja, Maticic Mojca
Abstract excerpt
OBJECTIVES: The combination of pegylated interferon-α and ribavirin is a standard-of-care (SOC) treatment for chronic hepatitis C (CHC), and it achieves a sustained virological response (SVR) in 41-52% of genotype 1 and in 73-79% of genotype 3 patients. In a few clinical trials, the combination of fluvastatin and SOC increased the SVR in genotype 1 patients. METHODS: This prospective study enrolled 179 naïve CHC...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.